JP2019532631A5 - - Google Patents

Download PDF

Info

Publication number
JP2019532631A5
JP2019532631A5 JP2019515292A JP2019515292A JP2019532631A5 JP 2019532631 A5 JP2019532631 A5 JP 2019532631A5 JP 2019515292 A JP2019515292 A JP 2019515292A JP 2019515292 A JP2019515292 A JP 2019515292A JP 2019532631 A5 JP2019532631 A5 JP 2019532631A5
Authority
JP
Japan
Prior art keywords
virus
seq
peptide
tumor
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019515292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019532631A (ja
JP7258746B2 (ja
Filing date
Publication date
Priority claimed from GBGB1616365.1A external-priority patent/GB201616365D0/en
Application filed filed Critical
Publication of JP2019532631A publication Critical patent/JP2019532631A/ja
Publication of JP2019532631A5 publication Critical patent/JP2019532631A5/ja
Priority to JP2022197406A priority Critical patent/JP2023029997A/ja
Application granted granted Critical
Publication of JP7258746B2 publication Critical patent/JP7258746B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019515292A 2016-09-27 2017-09-06 エンベロープウイルスの非遺伝的改変 Active JP7258746B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022197406A JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1616365.1A GB201616365D0 (en) 2016-09-27 2016-09-27 Non-genetic modification of enveloped viruses
GB1616365.1 2016-09-27
PCT/EP2017/072366 WO2018059896A1 (en) 2016-09-27 2017-09-06 Non-genetic modification of enveloped viruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022197406A Division JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Publications (3)

Publication Number Publication Date
JP2019532631A JP2019532631A (ja) 2019-11-14
JP2019532631A5 true JP2019532631A5 (cg-RX-API-DMAC7.html) 2020-10-08
JP7258746B2 JP7258746B2 (ja) 2023-04-17

Family

ID=57539741

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019515292A Active JP7258746B2 (ja) 2016-09-27 2017-09-06 エンベロープウイルスの非遺伝的改変
JP2022197406A Pending JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022197406A Pending JP2023029997A (ja) 2016-09-27 2022-12-09 エンベロープウイルスの非遺伝的改変

Country Status (12)

Country Link
US (1) US10982194B2 (cg-RX-API-DMAC7.html)
EP (1) EP3519565A1 (cg-RX-API-DMAC7.html)
JP (2) JP7258746B2 (cg-RX-API-DMAC7.html)
KR (1) KR102599401B1 (cg-RX-API-DMAC7.html)
CN (1) CN109890957A (cg-RX-API-DMAC7.html)
AU (2) AU2017337753B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019005825A2 (cg-RX-API-DMAC7.html)
CA (1) CA3035104A1 (cg-RX-API-DMAC7.html)
GB (1) GB201616365D0 (cg-RX-API-DMAC7.html)
RU (1) RU2760521C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018059896A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201902388B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201907413D0 (en) * 2019-05-24 2019-07-10 Univ Helsinki Viral vector
EP3982980A4 (en) * 2019-06-12 2023-11-29 BioNTech US Inc. NEOANTIGEN COMPOSITIONS AND USES THEREOF
CA3152796A1 (en) * 2019-08-27 2021-03-04 Turnstone Biologics Corp. Methods for inducing an immune response against neoantigens
GB202013834D0 (en) * 2020-09-03 2020-10-21 Valo Therapeutics Oy PeptiVAX therapy
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1108047A1 (en) 1998-08-27 2001-06-20 Aventis Pharma S.A. Targeted adenovirus vectors for delivery of heterologous genes
MXPA01005389A (es) * 1998-11-30 2003-03-27 Cytos Biotechnology Ag Presentacion molecular ordenada de antigenos, metodos de preparacion y uso.
CN1477964A (zh) * 1999-04-15 2004-02-25 应用病毒治疗肿瘤
KR100773109B1 (ko) 1999-05-06 2007-11-02 웨이크 포리스트 유니버시티 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법
CA2390081C (en) * 1999-10-29 2011-07-05 University Of Southern California Modified viral surface proteins which bind to cells of tumor vasculature
MXPA04005382A (es) * 2001-11-07 2005-02-24 Mannkind Corp Vectores de expresion que codifican epitopes de antigenos asociados al objetivo y metodos para su diseno.
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
WO2004000220A2 (en) 2002-06-21 2003-12-31 Genetix Pharmaceuticals, Inc. Methods for purifying viral particles for gene therapy
US20070243170A1 (en) * 2002-10-07 2007-10-18 The University Of Chicago Targeting of Herpes Simplex Virus to Specific Receptors
CN101675993A (zh) * 2003-03-26 2010-03-24 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
HRP20120845T1 (hr) * 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US7432045B2 (en) * 2003-12-01 2008-10-07 Wisconsin Alumni Research Foundation Method of inhibiting influenza infection with antiviral peptides
SG149013A1 (en) * 2003-12-17 2009-01-29 Wyeth Corp Immunogenic peptide carrier conjugates and methods of producing same
EP1921149A1 (en) * 2006-11-13 2008-05-14 AEterna Zentaris GmbH Microorganisms as carriers of nucleotide sequences coding for antigens and protein toxins, process of manufacturing and uses thereof
JP2008136381A (ja) * 2006-11-30 2008-06-19 Japan Health Science Foundation 改変型アデノウイルスベクター及びその作製方法
WO2009117656A2 (en) 2008-03-21 2009-09-24 Vectorlogics,Inc. Capsid-incorporated antigen for novel adenovirus vaccine
NO2700405T3 (cg-RX-API-DMAC7.html) * 2008-05-29 2018-09-01
US10603351B2 (en) * 2008-08-21 2020-03-31 Turnstone Limited Partnership Engineered synergistic oncolytic viral symbiosis
ES2335077B1 (es) 2008-12-30 2011-02-02 Instituto Aragones De Ciencias De La Salud Formulaciones para el recubrimiento y transporte de diversos elementos hacia los tumores.
SG176554A1 (en) * 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
US20140140962A1 (en) 2011-04-29 2014-05-22 The Research Foundation Of State University Of New York Viruses modified with unnatural moieties and methods of use thereof
US20140349944A1 (en) * 2013-05-23 2014-11-27 Musc Foundation For Research Development Chaperone-based integrin inhibitors for the treatment of cancer and inflammatory diseases
ES2847305T3 (es) * 2013-08-22 2021-08-02 Univ Pittsburgh Commonwealth Sys Higher Education Terapias inmunooncolíticas
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
JP6705755B2 (ja) 2014-05-19 2020-06-03 バロ セラピューティクス オイValo Therapeutics Oy 癌ワクチン開発のための改変アデノウイルス

Similar Documents

Publication Publication Date Title
CY1124275T1 (el) Vsv/ndv υβριδικοι ιοι για την ογκολυτικη θεραπεια του καρκινου
Zamarin et al. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions
Swiecki et al. BST-2/tetherin: structural biology, viral antagonism, and immunobiology of a potent host antiviral factor
JP2017522025A5 (cg-RX-API-DMAC7.html)
JP2019513118A5 (cg-RX-API-DMAC7.html)
US20210169956A1 (en) Increased activity of oncolytic newcastle disease virus
RU2019110407A (ru) Негенетическая модификация оболочечных вирусов
JP2019526580A5 (cg-RX-API-DMAC7.html)
JP2019501671A5 (cg-RX-API-DMAC7.html)
RU2017103162A (ru) Онколитический вирус для экспрессии модуляторов иммунологических контрольных точек
JP2019508045A5 (cg-RX-API-DMAC7.html)
JP2010523471A5 (cg-RX-API-DMAC7.html)
JP2005521398A5 (cg-RX-API-DMAC7.html)
US10604741B2 (en) Compositions and methods for enhancing virus replication
JP2023542297A5 (cg-RX-API-DMAC7.html)
JP2020533411A5 (cg-RX-API-DMAC7.html)
TW202227126A (zh) 異源初免加強疫苗
FI3448879T3 (fi) Claudin-6 -peptidejä
JP2023529839A5 (cg-RX-API-DMAC7.html)
JP2023536466A5 (cg-RX-API-DMAC7.html)
Parzych et al. Influenza virus specific CD8+ T cells exacerbate infection following high dose influenza challenge of aged mice
JP2024534189A5 (cg-RX-API-DMAC7.html)
JP2024523329A5 (cg-RX-API-DMAC7.html)
RU2011120447A (ru) Эпитопные пептиды rab6kifl/kif20a и содержащие их вакцины
CN109890839A (zh) 识别sage1抗原短肽的t细胞受体